EFIS is a non-profit umbrella organisation that represents 36 European immunology societies. Via funding initiatives and awards, EFIS helps to support immunological research and education and strengthens scientific interaction via study groups, task forces and its triennial congress - the European Congress of Immunology (ECI).
EFIS is a non-profit umbrella organisation that represents 36 immunology societies in Europe. Via funding initiatives and awards, EFIS helps to support immunological research and education and strengthens scientific interaction via study groups, task forces and its triennial congress - the ECI.
8 Oct 2024
ACTERIA Prizes awarded by EFIS
The call for applications for the 2025 ACTERIA Prizes in immunology and allergology awarded by EFIS is now open!
14 Dec 2024
2025 - 2027 EFIS Board
Congratulations are in order for the members of the newly elected EFIS Board!
14 Dec 2024
2025 EFIS Eastern Star Awards
The call for applications for the 2025 EFIS Eastern Star Awards, addressed to Eastern European laboratories, will be launched on 1 October 2024.
View all news
At the EFIS General Assembly held during the 2024 ECI in Dublin, the new EFIS Board was elected. Continue reading to learn more about them.
Find out more
9 Dec 2024
Impressum
9 Dec 2024
Cover Story: Eur. J. Immunol. 12'24
9 Dec 2024
Issue Information: Eur. J. Immunol. 12'24
9 Nov 2024
B Cells With Complementary B Cell Receptors Can Kill Each Other
8 Nov 2024
Characterization of the Molecular Signature of Human Monocytes in Aging and Myelodysplastic Neoplasms
Soluble CTLA-4 – A confounding factor in CTLA-4 based checkpoint immunotherapy in cancer
Editorial Board
Early decrease of T-bet<sup>+</sup> B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients
NLRC3 affects the development of psoriasis by modulating the NF-κB signaling pathway mediated inflammatory response through its interaction with TRAF6
Th1 adjuvant ARNAX, in combination with radiation therapy, enhances tumor regression in mouse tumor-implant models
